MX2021000732A - Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham. - Google Patents

Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham.

Info

Publication number
MX2021000732A
MX2021000732A MX2021000732A MX2021000732A MX2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A
Authority
MX
Mexico
Prior art keywords
ham
treatment
agent
htlv
prevention
Prior art date
Application number
MX2021000732A
Other languages
English (en)
Spanish (es)
Inventor
Yoshihisa Yamano
Kaoru Uchimaru
Makoto Yamagishi
Izumi Ishizaki
Original Assignee
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo filed Critical Univ Tokyo
Publication of MX2021000732A publication Critical patent/MX2021000732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021000732A 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham. MX2021000732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Publications (1)

Publication Number Publication Date
MX2021000732A true MX2021000732A (es) 2021-04-28

Family

ID=69163691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000732A MX2021000732A (es) 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham.

Country Status (16)

Country Link
US (1) US20210269535A1 (cg-RX-API-DMAC7.html)
EP (2) EP4656657A3 (cg-RX-API-DMAC7.html)
JP (4) JP7150286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034055A (cg-RX-API-DMAC7.html)
CN (4) CN116850291A (cg-RX-API-DMAC7.html)
AU (1) AU2019306721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112511A1 (cg-RX-API-DMAC7.html)
IL (1) IL280257A (cg-RX-API-DMAC7.html)
MX (1) MX2021000732A (cg-RX-API-DMAC7.html)
PE (2) PE20260298A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550134A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100561QA (cg-RX-API-DMAC7.html)
TW (2) TWI825131B (cg-RX-API-DMAC7.html)
WO (1) WO2020017629A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101113B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025070749A1 (cg-RX-API-DMAC7.html) * 2023-09-29 2025-04-03

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005087268A1 (ja) * 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102131571B (zh) 2008-09-02 2014-03-05 东丽电池隔膜株式会社 微孔性高分子膜、该膜的制备方法及该膜作为电池隔膜的应用
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法
KR102284780B1 (ko) 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
CA2824515C (en) * 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症患者の治療方法および治療剤
WO2016038084A1 (en) 2014-09-10 2016-03-17 AbbVie Deutschland GmbH & Co. KG Rgma fragment based diagnostic assay
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW202523689A (zh) * 2016-06-01 2025-06-16 美商艾伯維有限公司 治療脊髓損傷及疼痛之方法
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Also Published As

Publication number Publication date
TW202408577A (zh) 2024-03-01
JP2024095754A (ja) 2024-07-10
KR20210034055A (ko) 2021-03-29
CN112566664B (zh) 2023-08-25
CN112566664A (zh) 2021-03-26
CN116942831A (zh) 2023-10-27
PE20211376A1 (es) 2021-07-27
JPWO2020017629A1 (ja) 2021-08-02
PE20260298A1 (es) 2026-02-10
ZA202101113B (en) 2022-07-27
CN116850291A (zh) 2023-10-10
JP2022180487A (ja) 2022-12-06
JP2025134820A (ja) 2025-09-17
CA3112511A1 (en) 2020-01-23
EP3824907B1 (en) 2025-09-17
SG11202100561QA (en) 2021-02-25
IL280257A (en) 2021-03-25
WO2020017629A1 (ja) 2020-01-23
EP3824907A1 (en) 2021-05-26
TWI825131B (zh) 2023-12-11
EP3824907A4 (en) 2022-05-04
EP4656657A3 (en) 2026-02-25
JP7475011B2 (ja) 2024-04-26
AU2019306721A1 (en) 2021-03-11
PH12021550134A1 (en) 2021-09-27
EP4656657A2 (en) 2025-12-03
CN116785439A (zh) 2023-09-22
JP7703174B2 (ja) 2025-07-07
BR112021000949A2 (pt) 2021-04-27
AU2019306721B2 (en) 2024-09-05
JP7150286B2 (ja) 2022-10-11
TW202019482A (zh) 2020-06-01
US20210269535A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY192088A (en) Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12016502355B1 (en) Pharmaceutical composition
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MY201629A (en) Benzopyrazole compounds and analogues thereof
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
PH12021550713A1 (en) Medicament for the treatment of chronic cough
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2020000806A (es) Composicion para su uso en la prevencion y el tratamiento de patologias del aparato cardiovascular.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2021005944A (es) Inhibidores de rip1.
WO2019115493A3 (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
PH12021550134A1 (en) Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
MX2020011912A (es) Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).
MX2022015279A (es) Diagnostico, prevencion y tratamiento de la infeccion por coronavirus.
WO2021136841A3 (fr) Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires